The Legal 500

Twitter Logo Youtube Circle Icon LinkedIn Icon

Kirkland & Ellis LLP

Work +1 212 446 4800
Fax +1 212 446 4900

Jay Lefkowitz

Work +1 212-446-4970
Kirkland & Ellis LLP

Work Department



A senior litigation partner and member of Kirkland's Worldwide Management Committee, Jay Lefkowitz focuses on high-profile matters affecting the world’s leading companies in a wide range of industries including pharmaceuticals, private equity, technology and telecommunications. Jay represents clients on pivotal issues within the appellate space as well as securities and shareholders, government investigations, and commercial litigation. One of his two recent Supreme Court victories, Bartlett v. Mutual, a failure to warn and design defect pharmaceutical case, was described as “the most closely watched product liability case of 2013.” Jay is also a leading advocate for education reform, representing parents and children pro bono.


Columbia College, AB, 1984; Columbia Law School, JD, 1987.

United States: Antitrust

Civil litigation/class actions

Within: Civil litigation/class actions

Kirkland & Ellis LLP’s client base, which includes the Chicago Cubs, Bain Capital and EVA Air, reflects its breadth of expertise. Esteemed litigator James Mutchnik, based in Washington DC, was particularly active in 2015, and highlights included defending Health Care Services Corporation against allegations of suppressing competition for outpatient surgical services brought by a private clinic, and defending, as part of a cross-office team, Hitachi and Hitachi Display Products in multiple class actions alleging price-fixing of cathode ray tubes. In Chicago - another key office for antitrust work within the firm’s wide network - David Zott and Daniel Laytin are representing the Blue Cross Blue Shield Association in a series of putative class actions challenging, under antitrust laws, the structure of the association’s health insurance provision. Jay Lefkowitz in New York and Karen Walker in Washington DC together handled a number of pharmaceutical-related cases. Since publication, Matthew Reilly has joined from Simpson Thacher & Bartlett LLP.

[back to top]

United States: Dispute resolution


Within: Appellate

Kirkland & Ellis LLP has a strong appellate practice, with a truly national presence. Christopher Landau’s successful representation of DirecTV in an important arbitration enforcement dispute is testament to the firm’s abilities; the case, heard in the US Supreme Court, also has implications for the sovereignty of federal law over state law. In a federal court of appeals case, the firm represented Facebook in the dismissal of derivative actions bought by directors in the wake of its $16bn IPO in 2012. Highlights for Jay Lefkowitz include successfully defending Teva Pharmaceuticals in personal injury. Following publication, the firm subsumed the practice of leading Supreme Court law firm Bancroft PLLC. Those joining include ‘prolific’ practice head and former US Solicitor General Paul Clement, who had appeared at the Supreme Court over 75 times prior to 2015 - a number he added to over the course of the year in several major cases. In December, Clement argued the closely watched Supreme Court appeal for Franchise Tax Board of California in a case pertaining to the sovereignty of states in competition statutes. In October, Clement was retained by the appellant, the NFL, in the headline ‘deflategate’ litigation, which concerns the suspension of star quarterback Tom Brady for his knowledge of deflated footballs used in a game between the New England Patriots and the Indianapolis Colts; this case is ongoing. The legacy practice is also highly active in the federal courts of appeal, with HSBC a prestigious new client win; Clement successfully cleared a $2.5bn jury verdict concerning allegations that HSBC executives had misrepresented various company practices, including lending and accounting.

[back to top]

M&A: litigation: defense

Within: M&A: litigation: defense

Kirkland & Ellis LLP’s New York-based team continues to build upon a strong track record, with highlights including Yosef Riemer (‘certainly one of the leading lawyers in this area’) securing a major victory for Bain Capital and Golden Gate Capital in the largest statutory appraisal action ever to reach a post-trial decision in the Delaware Court of Chancery. Following the $6.9bn acquisition of BMC Software, the court ruled in favor of the firm’s clients in finding that merger price, rather than discounted cash flow, is the best indicator of fair value in the case of a robust and arm’s-length sales process. ‘Fine lawyerJay Lefkowitz, Matthew Solum and former director of enforcement at the SEC Robert Khuzami were part of a team that represented activist investor Pershing Square Capital Management in litigation arising from its joint bid with Valeant Pharmaceuticals to acquire Allergan and in a subsequent SEC inquiry. The firm also advised Vista Equity Partners in a class action arising from its acquisition of TIBCO Software, in which the target’s shareholders challenged the per-share valuation of the deal and alleged breach of fiduciary duty by the company’s board of directors.

[back to top]

Product liability, mass tort and class action: consumer products (including tobacco)

Within: Product liability, mass tort and class action: consumer products (including tobacco)

The Washington DC-based team of Kirkland & Ellis LLP, led by Eugene Assaf and Michael Williams, is currently serving as national and lead trial counsel to BASF Catalysts in a number of high-profile product liability cases arising from the sale of talc by the defunct talc-mining operations of Engelhard. New York-based Jay Lefkowitz successfully obtained dismissal of all claims brought against Teva Pharmaceutical Industries alleging failure to warn regarding the drug Treanda, a case heard before the US District Court for the Southern District of New York. Andrew McGaan is also recommended. Other clients include Honeywell and Union Carbide.

[back to top]

Product liability, mass tort and class action: pharmaceuticals and medical devices - defense

Within: Product liability, mass tort and class action: pharmaceuticals and medical devices - defense

Kirkland & Ellis LLP’s deep bench of litigation experts recently achieved a significant number of victories for key clients in the pharmaceuticals and healthcare sectors. Chicago-based Michael Foradas secured summary judgment for AbbVie in the final pending case involving the client’s Humira drug. New York-based Jay Lefkowitz successfully obtained dismissal of all claims brought against Teva Pharmaceuticals regarding alleged failure to warn of side effects associated with Treanda, a cancer treatment, in the US District Court for the Southern District of New York. Other clients of the practice include Baxter and Abbott Laboratories. Washington DC-based Mike Brock is highly recommended and has extensive experience in top-end litigation.

[back to top]

United States: Intellectual property

Trade secrets

Within: Trade secrets

A leading player in this field, Kirkland & Ellis LLP draws on its extensive litigation practice and highly regarded IP group to service its international client base. The department has a good standing in several industries, notably food and beverage, where Michael Slade defended Natural American Foods and its employee Arlen Penner in a case brought by Barkman Honey alleging breach of a non-compete agreement and tortious interference with a contract. Craig Primis and Daniel Bress are representing multinational conglomerate Honeywell in a North Carolina lawsuit alleging that Honeywell misappropriated trade secrets when it hired an employee who previously worked at DSM Dyneema, a competitor in the manufacture of ballistic materials for the US military. Another focus is the pharmaceutical industry; Nader Boulos and Jay Lefkowitz are defending Akorn in a case brought by Fera Pharmaceuticals regarding a manufacturing and supply agreement alleging that Akorn breached the parties’ contract by failing to manufacture certain products and misappropriating trade secrets.

[back to top]

Back to index

Legal Developments worldwide

Legal Developments and updates from the leading lawyers in each jurisdiction. To contribute, send an email request to
  • Innovation & Thailand 4.0: Value Creation for Business using Trade Secrets

    Thailand 4.0 stands for the new stage to transform the country currently relying on heavy industries (3.0 stage) into a creativity and innovation-driven economy. Trade secrets are definitively value-based and could help pursing Thailand 4.0.
  • Novelties Introduced by the Movable Pledge Law

    As of January 1, 2017, Law No. 6750 on Pledge over Movable Assets in Commercial Transactions (“Movable Pledge Law “), which was enacted on October 20, 2016, entered into force and abolished Law No.1447 on Commercial Enterprise Pledge (“Commercial Enterprise Pledge Law “). The Movable Pledge Law introduces significant changes and offers more practical methods for establishing pledge over movable assets as explained below.
  • Determination of Injury in Anti-Dumping Investigations: Turkey’s Side of the Story

    I - Introduction
  • Tax evasion: Only voluntary disclosure affords protection from severe penalties

    Anyone who has been caught for tax evasion should expect to be faced with severe penalties. Voluntary disclosure is the only way of returning to a state of normal tax affairs and avoiding penalties.
  • Turkish Health PPP Projects

    The Turkish health sector has undergone major reforms over the past ten years as part of the health transformation program. The most important pillar of such program has been the development of public-private partnership (“PPP ”) model health campus projects. More than twenty health campus projects with an investment amount of more than € 10 billion have been developed through PPP model in Turkey. They are currently at different stages ranging from tendering to operation, and more than ten health PPP projects are still in the pipeline.
  • Infrastructure REIC: An Alternative Source of Funding for Infrastructure Projects

    With the start of operation in certain BOT and other PPP model infrastructure projects in Turkey, refinancing alternatives have become more attractive and diversified. Capital market instruments and institutions are likely to have a greater share in the refinancings of projects which have become operational and the construction risks have been removed. Over the last few years, the use of capital market instruments in the infrastructure financings have gained a new impetus with the introduction of various incentives and financing solutions in this aspect. Most recently, the removal of the 1/3 and 1/5 bond issuance limits for healthcare PPP projects on 18 February 2017 represented an important step towards incentivizing the use of bonds in the healthcare sector. In line with this overall strategy, the government has also adopted various measures to make the Real Estate Investment Companies (“REICs ”) more attractive for the financing/refinancing of infrastructure projects such as BOT, BLT and other PPP projects.
  • Ankara-Niğde Highway Project

    Tender process for 330 km Ankara-Niğde Highway Project has been launched by the General Directorate of Highways upon publication of the tender announcement in the Official Gazette on December 30, 2016.
  • Establishment of the Natural Gas Spot Market in Turkey

    In line with the government’s objectives to make Turkey a regional hub for natural gas trading, a natural gas spot market has been established by the Natural Gas Organized Wholesale Market Regulation published in the Official Gazette on 31 March 2017.
  • Philippine Court of Appeals Denies Issuance of Environmental Protection Order Against Mining Company

    In a decision issued on March 8, 2017, the Philippine Court of Appeals (CA) denied the petition by NGO Ang Aroroy ay Alagaan, Inc. and certain individuals, for the issuance of a writ of kalikasan against Filminera Resources Corporation, and its directors and officers. The petitioners have claimed that Filminera, which operates in the Philippine province of Masbate, had been causing environmental damage in the conduct of its mining operations in violation of local law, and that a writ of kalikasan should be issued.

    Lis Alibi pendens is Latin for ‘suit pending elsewhere .’ Both Articles 27 and 28 of the EU Regulation 44/2001 regulate the existence of lis alibi pendens and related judicial actions. In particular it is a doctrine that regulates the jurisdictional relationship of courts hearing concurrent proceedings involving the same or related causes of action between the same parties pending in the courts of different Member States.